12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Novartis, University of Pennsylvania deal

The university granted Novartis exclusive, worldwide rights to develop and commercialize chimeric antigen receptor (CAR) immunotherapies for cancer. CAR-based immunotherapies are autologous T cells loaded with a lentiviral vector expressing a CAR, which consists of a cancer antigen-binding domain linked...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >